实用临床医药杂志2011，Vol.15Issue(23)：83-84,2.
索拉非尼治疗晚期原发性肝癌18例疗效及不良反应分析
Analysis of effects and adverse reactions of Sorafenib on 18 cases with advanced hepatocellular carcinoma
崔勇霞 1罗执芬 1周建炜 1周云1
作者信息
- 1. 河南省人民医院肿瘤内科,河南郑州,450003
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and adverse reactions of Sorafenib in the treatment of advanced hepatocellular carcinoma. Methods The clinical data of 18 cases with hepato-cellular carcinoma who were treated with Sorafenib from October 2009 to June 2011 were summarized. The objective effect, progression time, survival rate of six months and one year, quality of life and adverse reactions were evaluated during the treatment. Results After 8 weeks, 18 patients achieved SD (100.00%). After 16 weeks, one patient received PR (5.56%), 13 patients achieved SD (72.22%) and 4 patients got PD (22. 22%). The median progression time was 5. 8 months, the 6 - month survival rate was 94. 44% (17/18), and one - year survival rate was 50. 00% (9/ 18). The quality of life showed that 6 cases (33. 33%) were improved, 8 cases (44. 44%) were stable, 4 cases (22.22%) were decreased. Most adverse reactions occurred in level 1 and 2. Conclusion Sorafenib can improve 6 - month and 1 - year survival rate of patients with advanced hepatocellular carcinoma, and is well tolerated.关键词
索拉非尼/晚期原发性肝癌/毒副反应Key words
Sorafenib/ advanced, hepatocellular carcinoma/ adverse reactions分类
医药卫生引用本文复制引用
崔勇霞,罗执芬,周建炜,周云..索拉非尼治疗晚期原发性肝癌18例疗效及不良反应分析[J].实用临床医药杂志,2011,15(23):83-84,2.
